Napo Pharmaceuticals to be Keynote Speaker at Monaco Growth Investor Conference in U.A.E.


Napo to Participate in MGF’s Tech Tour U.A.E. and the MGF Spring Edition Investor Conference in Napa Valley

(SAN FRANCISCO) — February 3, 2017 — Napo Pharmaceuticals, Inc. (Napo) is pleased to announce that its CEO and founder, Lisa Conte, will be the keynote speaker at the Monaco Growth Forums Tech Tour, taking place in the United Arab Emirates, from February 20th – 23rd, at The Ritz-Carlton in Abu Dhabi, and in Dubai at The Address Hotel at The Dubai Mall.

San Francisco-based Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals from rainforest resources for the global marketplace in collaboration with local partners. In October 2016, Napo launched Mytesi™ (formerly known as Fulyzaq), a human drug approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Ms. Conte will conduct a corporate presentation at the Tech Tour U.A.E. event and discuss recent business highlights with number of institutional investment firms in the Dubai region. This exclusive three-day gathering will allow top emerging growth companies, established institutional investors, and industry professionals the unique opportunity to network with one another.

In addition, Ms. Conte will also be presenting at the MGF Spring Edition investor conference in Napa Valley, California from March 29-31, 2017, which will feature leading healthcare companies.

“I look forward to presenting at both of these events to familiarize investors in the U.A.E. and Napa Valley regions with Napo and our plans to develop Mytesi™ for additional indications, both for the human market and, through our partners, for animals, including equine athletes, dogs, and dairy cattle,” commented Conte.

Andreea Porcelli, CEO of Monaco Growth Forums Ltd., noted, “We are thrilled to introduce emerging healthcare companies, such as Napo Pharmaceuticals, to our select audience of institutional investors, family offices, and funding partners in the U.A.E. and Napa Valley, California. Napo offers a unique technology that fits well for an international stage.”

For more information or to RSVP for the Tech Tour U.A.E. and MGF Spring Edition events and one-on-one investor meetings with Napo, contact Sevinc Bermek, Events Coordinator:

About Monaco Growth Forums, Ltd.
Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andrea Porcelli, MGF founder and president, has more than 20 years’ experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high net-worth individuals, and industry-related sponsors and foundations—all of whom are also exclusively invited to match MFG’s highly selective criteria. Error! Hyperlink reference not valid.

About Mytesi™
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at


KCSA Strategic Communications
Garth Russell, 212-896-1250


Monaco Growth Forums
Eduardo Robinson, 855-776-5763